APEX1 and central nervous system cancer: Moreover, in preclinical studies, antisense oligonucleotides directed APE1 depletion in SNB19, a human glioma cell line lacking O(6)-methylguanine-DNA-methyltransferase, lead to potentiation of MMS and temozolomide cytotoxicity, implying that pharmacological modulation of APE1 is a promising strategy in glioma (Silber et al, 2002).